Optimization of Expression Construct and Purification Protocols for a MSP1.42 Malaria Vaccine

Category: Biology and Medicine

Reference Number: 00310

Description

The invention consists of two parts which both contribute to an enhanced feasibility of commercial production of this potential malaria vaccine: (1) optimization of the MSP1.42 gene construct for enhanced levels of production in the baculovirus/insect cell culture expression system, and (2) development of a simplified, non-denaturing purification scheme which enhances recovery and purity of the MSP1.42 polypeptide.

Applications

Malaria vaccine

Main Advantages

Approximately 5-10 fold increases in the level of expression of the recombinant polypeptide were achieved for insect cell cultures infected with recombinant baculovirus containing the optimized MSP1.42 construct. The simplified purification scheme utilizes commercially available column matrixes to purify MSP1.42 to homogeneity and at high yield in a few steps.

Inventor(s)

Sandra Chang, Ann Hashimoto, Tani Nishimura
Tropical Medicine & Medical Microbiology

Contact Information

For licensing information, please contact Lisa Matsunaga at matsunag@hawaii.edu

For all other inquiries, please write to:

Office of Technology Transfer & Economic Development
University of Hawai’i
2800 Woodlawn Drive, Suite 280
Honolulu, HI 96822